Table 3.

This table summarizes the trials investigating the use of cyclin-dependent kinase inhibitors in the adjuvant setting.

Trial	Year	Status	Patient Population	Intervention	Control Arm	Primary Outcome
PENELOPE-B (NCT01864746)	2013–2020	Completed	HR+, HER2− EBC	PAL (125 mg once daily for 13 cycles) + ≥5 years ET	ET + placebo	42.8-month iDFS: no difference; (HR = 0.93, 95% CI: 0.74–1.17); two-sided weighted log-rank test (Cui, Hung, and Wang) p = 0.525
PALLAS (NCT02513394)	2015–2020	Completed	HR+, HER2− EBC	PAL (125 mg orally once daily for 2 years) + ≥5 years ET	ET alone	31-month iDFS: 8.8% PAL + ET vs. 9.1% ET, iDFS at 4 years: 84.2% vs. 84.5% (HR = 0.96, 95% CI: 0.81–1.14, p = 0.65)
MonarchE (NCT03155997)	2017–2020	Completed	HR+, HER2− EBC	Abemaciclib (150 mg twice daily for 2 years) + ET ≥5 years	ET alone	3-year iDFS improved by 5.4% in the abemaciclib group (HR = 0.70, 95% CI: 0.59–0.82)
MonarchE (NCT03155997)	2018–2026	Active	HR+, HER2− EBC	RIBO (400 mg/day 3 weeks on, 1 week off for 3 years) + ET ≥5 years	ET alone	34-month iDFS improved by 3.3% in the RIB + ET group; iDFS (HR, 0.748; 95% CI, 0.618–0.906; p = 0.0014); 3-year iDFS rates: 90.4% vs. 87.1%